Information Provided By:
Fly News Breaks for February 26, 2020
BTAI
Feb 26, 2020 | 07:38 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $95 from $30 and reiterates a Buy rating on the shares. Following an assessment of the five indications in which BXCL501 could potentially be deployed, schizophrenia, bipolar disorder, Alzheimer's disease, opioid use disorder and acute delirium , the analyst instituted an updated valuation assessment. His assessment yields a total value of $2B for BXCL501 across the aforementioned indications.